WuXi PharmaTech's Small-Molecule Manufacturing Subsidiary STA Wins CMO Leadership Award
SHANGHAI, Jan. 30, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, announced today that SynTheAll Pharmaceutical Co., Ltd. (STA), WuXi's small-molecule manufacturing subsidiary, has won a 2015 CMO Leadership Award, which is presented by Life Science Leader magazine based on research conducted by Nice Insight. STA has won in the perception category of Reliability in the company category of Big Pharma. The award is based on the survey responses of more than 2,300 pharmaceutical and biopharmaceutical professionals. WuXi and STA also received a CMO Leadership Award for Quality in 2012.
"On behalf of 1,500 highly dedicated employees at STA, I am very pleased to accept this award," said Dr. Minzhang Chen, Senior Vice President of WuXi PharmaTech and General Manager of STA. "Every day we at STA strive to provide our customers with the highest quality of services across our integrated small-molecule API development and manufacturing platform from process chemistry to research and commercial manufacturing."
STA continues to invest in new capabilities and capacity. Its high-potency development and GMP labs in Shanghai began operations in 2014. In collaboration with its partners, STA is in the process of building its continuous processing and biocatalysis technology platforms. Its new Changzhou campus is currently under construction. Upon the completion of this $140 million investment, STA's capacity in both process chemistry and research and commercial manufacturing will double to meet the growing demand for its services.
"I am especially pleased that STA received this recognition from our most important audience--our customers," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This is the second time we have won this award, and it reflects our long-time commitment to our partners worldwide in the discovery, development, and commercialization of new medicines to benefit the world's patients."
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For further information, please visit http://www.wuxiapptec.com.
Contacts:
Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech
+1-201-585-2048
[email protected]
Aaron Shi
Director of Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
[email protected]
SOURCE WuXi PharmaTech
Share this article